{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:14:49Z","timestamp":1758039289459,"version":"3.44.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ad.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T01:11:54Z","timestamp":1602292314000},"page":"118-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["F\u00e1rmacos de uso frecuente en dermatolog\u00eda como terapia para COVID-19"],"prefix":"10.1016","volume":"112","author":[{"given":"M.","family":"Ortega-Pe\u00f1a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gonz\u00e1lez-Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2020.09.004_bib0470","first-page":"1188","article-title":"The history and lore of cinchona","volume":"2","author":"Thompson","year":"1928","journal-title":"Br Med J."},{"key":"10.1016\/j.ad.2020.09.004_bib0475","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1095-8339.1949.tb00419.x","article-title":"A critical review of the basic facts in the history of cinchona","volume":"53","author":"Jaramillo-Arango","year":"1949","journal-title":"Bot J Linn Soc."},{"year":"2018","series-title":"Cinchona bark","author":"Burba","key":"10.1016\/j.ad.2020.09.004_bib0480"},{"key":"10.1016\/j.ad.2020.09.004_bib0485","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1473-3099(15)00246-7","article-title":"In celebration of the Jesuit's powder: A history of malaria treatment","volume":"15","author":"Harrison","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.09.004_bib0490","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1540-8167.1994.tb01304.x","article-title":"Stories about the origin of quinquina and quinidine","volume":"5","author":"Levy","year":"1994","journal-title":"J Cardiovasc Electrophysiol."},{"key":"10.1016\/j.ad.2020.09.004_bib0495","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(14)61786-4","article-title":"How World War 1 changed global attitudes to war and infectious diseases","volume":"384","author":"Shanks","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.09.004_bib0500","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/toxins10120491","article-title":"The fever tree: From malaria to neurological diseases","volume":"10","author":"Eyal","year":"2018","journal-title":"Toxins (Basel)."},{"key":"10.1016\/j.ad.2020.09.004_bib0505","first-page":"223","article-title":"A posgraduate lecture on lupus erythematosus","volume":"4","author":"Payne","year":"1894","journal-title":"Clin J."},{"key":"10.1016\/j.ad.2020.09.004_bib0510","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.1943.82840390004007","article-title":"Circular letter N 153 The drug treatment of malaria, suppressive and clinical","volume":"123","year":"1943","journal-title":"JAMA."},{"key":"10.1016\/j.ad.2020.09.004_bib0515","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/archdermatol.2011.191","article-title":"Response to antimalarial agents in cutaneous lupus erythematosus: A prospective analysis","volume":"147","author":"Chang","year":"2011","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.ad.2020.09.004_bib0520","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0140-6736(51)91643-1","article-title":"Treatment of lupus erythematosus with mepacrine","volume":"2","author":"Page","year":"1951","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.09.004_bib0525","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1177\/0961203396005001021","article-title":"The history of antimalarials","volume":"5","author":"Wallace","year":"1996","journal-title":"Lupus."},{"key":"10.1016\/j.ad.2020.09.004_bib0530","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ad.2009.07.002","article-title":"Aspectos pr\u00e1cticos de la quinacrina como tratamiento del lupus eritematoso cut\u00e1neo: serie de casos","volume":"101","author":"Gonz\u00e1lez-Sixto","year":"2010","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2020.09.004_bib0535","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J."},{"key":"10.1016\/j.ad.2020.09.004_bib0540","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: An old drug against today's diseases","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.ad.2020.09.004_bib0545","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1083\/jcb.90.3.656","article-title":"Cytoplasmic Vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances","volume":"90","author":"Ohkuma","year":"1981","journal-title":"J Cell Biol."},{"key":"10.1016\/j.ad.2020.09.004_bib0550","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0555","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci Trends."},{"key":"10.1016\/j.ad.2020.09.004_bib0560","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.ad.2020.09.004_bib0565","first-page":"1620","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Nat","volume":"11","author":"Ou","year":"2020","journal-title":"Commun."},{"key":"10.1016\/j.ad.2020.09.004_bib0570","doi-asserted-by":"crossref","first-page":"106028","DOI":"10.1016\/j.ijantimicag.2020.106028","article-title":"A review on possible modes of action of chloroquine\/hydroxychloroquine: Repurposing against SAR-CoV-2 (COVID-19) pandemic","volume":"56","author":"Tripathy","year":"2020","journal-title":"Int J Antimicrob Agents."},{"issue":"10223","key":"10.1016\/j.ad.2020.09.004_bib0575","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.09.004_bib0580","first-page":"E005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi."},{"key":"10.1016\/j.ad.2020.09.004_bib0585","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"10.1016\/j.ad.2020.09.004_bib0590","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: An old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.ad.2020.09.004_bib0595","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ad.2020.09.004_bib0600","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.ad.2020.09.004_bib0605","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2020.09.004_bib0610","first-page":"31180-6","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis","volume":"S0140-6736","author":"Mehra","year":"2020","journal-title":"Lancet."},{"issue":"10240","key":"10.1016\/j.ad.2020.09.004_bib0615","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0140-6736(20)31324-6","article-title":"Retraction-hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis [retraction of: Lancet 2020 May 22]","volume":"395","author":"Mehra","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.09.004_bib0620","first-page":"30240","article-title":"COVID-19 and hydroxychloroquine: Is the wonder drug failing? [published online ahead of print, 2020 Jun 4]","volume":"S0953-6205","author":"Paliani","year":"2020","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.ad.2020.09.004_bib0625","doi-asserted-by":"crossref","unstructured":"Mitj\u00e0 O. Ubals M. Corbacho-Monn\u00e9 M. Alemany A. Su\u00f1er C. Tebe C. et al. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease. Medrxiv. https:\/\/doi.org\/10.1101\/2020.07.20.20157651.","DOI":"10.1101\/2020.07.20.20157651"},{"key":"10.1016\/j.ad.2020.09.004_bib0630","doi-asserted-by":"crossref","unstructured":"Million M, Gautretac P, Colson P, Roussel Y, Dubourg G, Chabriere E, et al. Clinical efficacy of chloroquine derivatives in COVID-19 infection: Comparative meta-analysis between the big data and the real world. New Microbes New Infect. 2020;38:100709. https:\/\/doi.org\/10.1016\/j.nmni.2020.100709.","DOI":"10.1016\/j.nmni.2020.100709"},{"key":"10.1016\/j.ad.2020.09.004_bib0635","first-page":"30266","article-title":"Chloroquine and COVID-19: A western medical and scientific drift?","volume":"S0953-6205","author":"Million","year":"2020","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.ad.2020.09.004_bib0640","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nrmicro1048","article-title":"The life and times of ivermectin: A success story","volume":"2","author":"\u014cmura","year":"2004","journal-title":"Nat Rev Microbiol."},{"key":"10.1016\/j.ad.2020.09.004_bib0645","unstructured":"Campbell WC The genesis of the antiparasitic drug ivermectin. En: Weber RJ, Perkins DN, editores. Inventive minds. New York: Oxford University Press: 1992. p. 194-214 [consultado 27 Ago 2020]. Disponible en: https:\/\/books.google.cl\/books?hl=es&lr=&id=VU885vUQ9bQC&oi=fnd&pg=PA194&dq=Campbell,+W.C.+(1992)+The+genesis+of+the+antiparasitic+drug+ivermectin.++In++Inventive+Minds+(eds.+Weber,+R.J.+and+Perkins,+D.N.).+Oxford+University+Press,+New+York,+pp.+194%E2%80%93214.+&ots=-By6K-qIp6&sig=MupzZGOw_YZP23l-MKjhBsp_lSA&redir_esc=y#v=onepage&q&f=false"},{"key":"10.1016\/j.ad.2020.09.004_bib0650","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1128\/AAC.15.3.361","article-title":"Avermectins, new family of potent anthelmintic agents: producing organism and fermentation","volume":"15","author":"Burg","year":"1979","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ad.2020.09.004_bib0655","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1128\/AAC.15.3.368","article-title":"Avermectins, new family of potent anthelmintic agents: Isolation and chromatographic properties","volume":"15","author":"Miller","year":"1979","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ad.2020.09.004_bib0660","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1128\/AAC.15.3.372","article-title":"Avermectins, new family of potent anthelmintic agents: Efficacy of the B1a component","volume":"15","author":"Egerton","year":"1979","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.ad.2020.09.004_bib0665","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/infdis\/156.3.463","article-title":"Controlled trial and dose-finding study of ivermectin for treatment of infectious diseases","volume":"156","author":"White","year":"1987","journal-title":"J Infect Dis."},{"key":"10.1016\/j.ad.2020.09.004_bib0670","first-page":"131","article-title":"Single dose therapy with ivermectin for onchocerciasis","volume":"100","author":"Greene","year":"1987","journal-title":"Trans Assoc Am Physicians."},{"key":"10.1016\/j.ad.2020.09.004_bib0675","doi-asserted-by":"crossref","first-page":"1047872","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0680","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/13102818.2020.1775118","article-title":"Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens","volume":"34","author":"Momekov","year":"2020","journal-title":"Biotechnol Biotechnol Equip."},{"key":"10.1016\/j.ad.2020.09.004_bib0685","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ad.2020.03.001","article-title":"Spironolactone in Dermatology: Uses in acne, hidradenitis suppurativa female pattern baldness, and hirsutism","volume":"111","author":"Vargas-Mora","year":"2020","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.ad.2020.09.004_bib0690","first-page":"23","article-title":"Enzalutamide and blocking androgen receptor in advanced prostate cancer: Lessons learnt from the history of drug development of antiandrogens","volume":"10","author":"Ito","year":"2018","journal-title":"Res Rep Urol."},{"key":"10.1016\/j.ad.2020.09.004_bib0695","series-title":"Hormone therapy in breast and prostate cancer. Cancer drug discovery and development","first-page":"325","article-title":"Steroidal antiandrogens","author":"Schr\u00f6der","year":"2009"},{"key":"10.1016\/j.ad.2020.09.004_bib0700","article-title":"Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men","author":"Ghazizadeh","year":"2020","journal-title":"bioRxiv. [Preprint]"},{"key":"10.1016\/j.ad.2020.09.004_bib0705","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jaad.2020.04.032","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated","volume":"83","author":"Wambier","year":"2020","journal-title":"J Am Acad Dermatol."},{"issue":"4.","key":"10.1016\/j.ad.2020.09.004_bib0710","article-title":"Virology, epidemiology pathogenesis, and control of COVID-19","volume":"12","author":"Jin","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.ad.2020.09.004_bib0715","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1128\/JVI.03372-12","article-title":"TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium","volume":"87","author":"Bertram","year":"2013","journal-title":"J Virol."},{"key":"10.1016\/j.ad.2020.09.004_bib0720","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.maturitas.2020.05.009","article-title":"Are we equal in adversity? Does Covid-19 affect women and men differently?","volume":"138","author":"Serge","year":"2020","journal-title":"Maturitas."},{"key":"10.1016\/j.ad.2020.09.004_bib0725","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/jocd.13443","article-title":"A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain \u2014A potential clue to the role of androgens in COVID-19 severity","volume":"19","author":"Goren","year":"2020","journal-title":"J Cosmet Dermatol."},{"key":"10.1016\/j.ad.2020.09.004_bib0730","article-title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: A population-based study (N =4532)","volume":"S0923\u20137534","author":"Montopoli","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ad.2020.09.004_bib0735","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Trial to promote recovery from COVID-19 with endocrine therapy (RECOVER) 2020 [consultado 19 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04374279?term=bicalutamide&cond=covid-19&draw=2&rank=1."},{"key":"10.1016\/j.ad.2020.09.004_bib0740","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Hormonal intervention for the treatment in veterans with COVID-19 requiring hospitalization (HITCH) 2020 [consultado 19 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04397718?term=degarelix&cond=covid-19&draw=2"},{"key":"10.1016\/j.ad.2020.09.004_bib0745","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jid.2017.10.025","article-title":"Melatonin: A cutaneous perspective on its production metabolism, and functions","volume":"138","author":"Slominski","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2020.09.004_bib0750","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/edrv-12-2-151","article-title":"Pineal melatonin: Cell biology of its synthesis and of its physiological interactions","volume":"12","author":"Reiter","year":"1991","journal-title":"Endocr Rev."},{"key":"10.1016\/j.ad.2020.09.004_bib0755","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s00018-017-2609-7","article-title":"Melatonin as a mitochondria-targeted antioxidant: One of evolution's best ideas","volume":"74","author":"Reiter","year":"2017","journal-title":"Cell Mol Life Sci."},{"key":"10.1016\/j.ad.2020.09.004_bib0760","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1152\/physrev.1950.30.1.91","article-title":"Biochemistry of melanin formation","volume":"30","author":"Lerner","year":"1950","journal-title":"Physiol Rev."},{"key":"10.1016\/j.ad.2020.09.004_bib0765","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/sj.jid.5701010","article-title":"Aaron Lerner: Perspectives and lessons learned from the melatonin days","volume":"127","author":"Barchas","year":"2007","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2020.09.004_bib0770","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-079X.2007.00457.x","article-title":"Aaron Lerner, who discovered melatonin","volume":"43","author":"Arendt","year":"2007","journal-title":"J Pineal Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0775","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1021\/ja01543a060","article-title":"Isolation of melatonin, pineal factor that lightens melanocytes","volume":"80","author":"Lerner","year":"1958","journal-title":"J Am Chem Soc."},{"key":"10.1016\/j.ad.2020.09.004_bib0780","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF02152134","article-title":"Sleep induced by the administration of melatonin (5-methoxyn-acetyltryptamine) to the hypothalamus in unrestrained cats","volume":"20","author":"Marczynski","year":"1964","journal-title":"Experientia."},{"key":"10.1016\/j.ad.2020.09.004_bib0785","doi-asserted-by":"crossref","first-page":"108448","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: Immunology and treatment options","volume":"215","author":"Felsensteina","year":"2020","journal-title":"Clin Immunol."},{"key":"10.1016\/j.ad.2020.09.004_bib0790","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jmv.24130","article-title":"Ebola virus: Melatonin as a readily available treatment option","volume":"87","author":"Anderson","year":"2015","journal-title":"J Med Virol."},{"key":"10.1016\/j.ad.2020.09.004_bib0795","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s13104-018-3417-3","article-title":"Screening of melatonin \u03b1-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity","volume":"11","author":"Paemanee","year":"2018","journal-title":"BMC Res Notes."},{"key":"10.1016\/j.ad.2020.09.004_bib0800","first-page":"193","article-title":"Melatonin prevents the decreased activity of antioxidant enzymes and activates nuclear erythroid 2-related factor 2 signaling in an animal model of fulminant hepatic failure of viral origin","volume":"49","author":"Crespo","year":"2010","journal-title":"J Pineal Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0805","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.brainres.2015.06.034","article-title":"Melatonin, minocycline and ascorbic acid reduce oxidative stress and viral titers and increase survival rate in experimental Venezuelan equine encephalitis","volume":"1622","author":"Valero","year":"2015","journal-title":"Brain Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0810","doi-asserted-by":"crossref","first-page":"43","DOI":"10.32794\/mr11250047","article-title":"Treatment of ebola and other infectious diseases: Melatonin \u201cgoes viral\u201d","volume":"3","author":"Reiter","year":"2020","journal-title":"Melatonin Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0815","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01309858","article-title":"Protective effects of melatonin in mice infected with encephalitis viruses","volume":"140","author":"Ben-Nathan","year":"1995","journal-title":"Arch Virol."},{"key":"10.1016\/j.ad.2020.09.004_bib0820","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s000180050051","article-title":"Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus","volume":"53","author":"Bonilla","year":"1997","journal-title":"Cell Mol Life Sci."},{"key":"10.1016\/j.ad.2020.09.004_bib0825","doi-asserted-by":"crossref","first-page":"117583","DOI":"10.1016\/j.lfs.2020.117583","article-title":"COVID-19: Melatonin as a potential adjuvant treatment","volume":"250","author":"Zhang","year":"2020","journal-title":"Life Sciences."},{"key":"10.1016\/j.ad.2020.09.004_bib0830","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.ad.2020.09.004_bib0835","first-page":"604","article-title":"[Inhibitory effect of melatonin on the expression of nuclear factor-kappaB during acute lung injury in rats]","volume":"20","author":"Zhang","year":"2008","journal-title":"Zhongguo Wei Zhong Bing Ji Jiu Yi Xue."},{"key":"10.1016\/j.ad.2020.09.004_bib0840","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10787-018-0539-0","volume":"27","author":"Bazyar","year":"2019","journal-title":"Inflammopharmacol."},{"key":"10.1016\/j.ad.2020.09.004_bib0845","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.arcmed.2018.12.004","article-title":"Efficacy of melatonin on serum pro-inflammatory cytokines and oxidative stress markers in relapsing remitting multiple sclerosis","volume":"49","author":"S\u00e1nchez-L\u00f3pez","year":"2018","journal-title":"Arch Med Res."},{"key":"10.1016\/j.ad.2020.09.004_bib0850","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00394-019-02123-0","article-title":"Melatonin supplementation and pro-inflammatory mediators: A systematic review and meta-analysis of clinical trials","volume":"59","author":"Zarezadeh","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.ad.2020.09.004_bib0855","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.ad.2020.09.004_bib0860","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/med.21257","article-title":"Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents","volume":"32","author":"Magesh","year":"2012","journal-title":"Med Res Rev."},{"key":"10.1016\/j.ad.2020.09.004_bib0865","first-page":"4087298","article-title":"Melatonin alleviates radiation-induced lung injury via regulation of miR-30e\/NLRP3 axis","author":"Wu","year":"2019","journal-title":"Oxid Med Cell Longev."},{"key":"10.1016\/j.ad.2020.09.004_bib0870","doi-asserted-by":"crossref","first-page":"117739","DOI":"10.1016\/j.lfs.2020.117739","article-title":"Comment on melatonin as a potential adjuvant treatment for COVID-19","volume":"253","author":"Herrera","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ad.2020.09.004_bib0875","doi-asserted-by":"crossref","first-page":"117716","DOI":"10.1016\/j.lfs.2020.117716","article-title":"Correspondence COVID-19: Melatonin as a potential adjuvant treatment","volume":"253","author":"Salles","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ad.2020.09.004_bib0880","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2020.04.009","article-title":"An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients","volume":"312","author":"Wang","year":"2020","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.ad.2020.09.004_bib0885","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2020.04.066","article-title":"COVID-19 and cardiovascular injury: A role for oxidative stress and antioxidant treatment?","volume":"312","author":"Loffredo","year":"2020","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.ad.2020.09.004_bib0890","doi-asserted-by":"crossref","first-page":"117808","DOI":"10.1016\/j.lfs.2020.117808","article-title":"Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment","volume":"254","author":"Mart\u00edn Gim\u00e9nez","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ad.2020.09.004_bib0895","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Efficacy of melatonin in the prophylaxis of coronavirus disease 2019 (COVID-19) among healthcare workers. (MeCOVID) 2020 [consultado 19 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04353128"},{"key":"10.1016\/j.ad.2020.09.004_bib0900","unstructured":"Registro Espa\u00f1ol de Estudios Cl\u00ednicos (reec). Ensayo cl\u00ednico para explorar la eficacia y seguridad de melatonina en pacientes con covid-19 ingresados en unidad de cuidados intensivos. 2020 [consultado 19 Jul 2020]. Disponible en: https:\/\/reec.aemps.es\/reec\/public\/detail.html"},{"key":"10.1016\/j.ad.2020.09.004_bib0905","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ."},{"key":"10.1016\/j.ad.2020.09.004_bib0910","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"10.1016\/j.ad.2020.09.004_bib0915","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J Crit Care."},{"key":"10.1016\/j.ad.2020.09.004_bib0920","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Ivermectin effect on SARS-CoV-2 replication in patients with COVID-19 2020 [consultado 24 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04381884?term=IVERMECTINA&cond=COVID19&draw=2&rank=2"},{"key":"10.1016\/j.ad.2020.09.004_bib0925","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. COVidIVERmectin: Ivermectin for treatment of Covid-19 (COVER) 2020 [consultado 24 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04438850?term=IVERMECTINA&cond=COVID19&draw=2&rank=4"},{"key":"10.1016\/j.ad.2020.09.004_bib0930","unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Anti-androgen treatment for COVID-19. 2020 [consultado 24 Jul 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04446429?term=antiandrogens&cond=covid19&draw=2&rank=1"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020303811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020303811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:11:12Z","timestamp":1757553072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731020303811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0001731020303811"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2020.09.004","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"F\u00e1rmacos de uso frecuente en dermatolog\u00eda como terapia para COVID-19","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}